FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3187715715> ?p ?o ?g. }

• W3187715715 abstract "To compare survival outcomes between bevacizumab (BEV) and olaparib (OLA) maintenance therapy in BRCA-mutated, platinum-sensitive relapsed (PSR) high-grade serous ovarian carcinoma (HGSOC).From 10 institutions, we identified HGSOC patients with germline and/or somatic BRCA1/2 mutations, who experienced platinum-sensitive recurrence between 2013 and 2019, and received second-line platinum-based chemotherapy. Patients were divided into BEV (n=29), OLA (n=83), and non-BEV/non-OLA users (n=36). The OLA and non-BEV/non-OLA users were grouped as the OLA intent group. We conducted 1:2 nearest neighbor-matching between the BEV and OLA intent groups, setting the proportion of OLA users in the OLA intent group from 65% to 100% at 5% intervals, and compared survival outcomes among the matched groups.Overall, OLA users showed significantly better progression-free survival (PFS) than BEV users (median, 23.8 vs. 17.4 months; p=0.004). Before matching, PFS improved in the OLA intent group but marginal statistical significance (p=0.057). After matching, multivariate analyses adjusting confounders identified intention-to-treat OLA as an independent favorable prognostic factor for PFS in the OLA 65P (adjusted hazard ratio [aHR]=0.505; 95% confidence interval [CI]=0.280-0.911; p=0.023) to OLA 100P (aHR=0.348; 95% CI=0.184-0.658; p=0.001) datasets. The aHR of intention-to-treat OLA for recurrence decreased with increasing proportions of OLA users. No differences in overall survival were observed between the BEV and OLA intent groups, and between the BEV and OLA users.Compared to BEV, intention-to-treat OLA and actual use of OLA maintenance therapy were significantly associated with decreased disease recurrence risk in patients with BRCA-mutated, PSR HGSOC." @default.
• W3187715715 created "2021-08-16" @default.
• W3187715715 creator A5017219746 @default.
• W3187715715 creator A5024381278 @default.
• W3187715715 creator A5025851069 @default.
• W3187715715 creator A5035365662 @default.
• W3187715715 creator A5040409719 @default.
• W3187715715 creator A5043069940 @default.
• W3187715715 creator A5049698155 @default.
• W3187715715 creator A5055872689 @default.
• W3187715715 creator A5059193002 @default.
• W3187715715 creator A5077229668 @default.
• W3187715715 creator A5077805782 @default.
• W3187715715 creator A5085553146 @default.
• W3187715715 date "2021-01-01" @default.
• W3187715715 modified "2023-09-25" @default.
• W3187715715 title "Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)" @default.
• W3187715715 cites W1793338775 @default.
• W3187715715 cites W1964736695 @default.
• W3187715715 cites W2002710053 @default.
• W3187715715 cites W2019607817 @default.
• W3187715715 cites W2053358503 @default.
• W3187715715 cites W2110790489 @default.
• W3187715715 cites W2160466424 @default.
• W3187715715 cites W2171658624 @default.
• W3187715715 cites W2528228811 @default.
• W3187715715 cites W2605456582 @default.
• W3187715715 cites W2737389832 @default.
• W3187715715 cites W2754327139 @default.
• W3187715715 cites W2897430921 @default.
• W3187715715 cites W2951714360 @default.
• W3187715715 cites W2970135300 @default.
• W3187715715 cites W2975141952 @default.
• W3187715715 cites W2984340295 @default.
• W3187715715 cites W2985168992 @default.
• W3187715715 cites W2994977341 @default.
• W3187715715 cites W3028607434 @default.
• W3187715715 cites W3029198420 @default.
• W3187715715 cites W3045015379 @default.
• W3187715715 cites W3048967410 @default.
• W3187715715 cites W3087988414 @default.
• W3187715715 cites W3128646645 @default.
• W3187715715 cites W3135376158 @default.
• W3187715715 cites W4236289131 @default.
• W3187715715 doi "https://doi.org/10.3802/jgo.2021.32.e90" @default.
• W3187715715 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8550925" @default.
• W3187715715 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34431258" @default.
• W3187715715 hasPublicationYear "2021" @default.
• W3187715715 type Work @default.
• W3187715715 sameAs 3187715715 @default.
• W3187715715 citedByCount "2" @default.
• W3187715715 countsByYear W31877157152023 @default.
• W3187715715 crossrefType "journal-article" @default.
• W3187715715 hasAuthorship W3187715715A5017219746 @default.
• W3187715715 hasAuthorship W3187715715A5024381278 @default.
• W3187715715 hasAuthorship W3187715715A5025851069 @default.
• W3187715715 hasAuthorship W3187715715A5035365662 @default.
• W3187715715 hasAuthorship W3187715715A5040409719 @default.
• W3187715715 hasAuthorship W3187715715A5043069940 @default.
• W3187715715 hasAuthorship W3187715715A5049698155 @default.
• W3187715715 hasAuthorship W3187715715A5055872689 @default.
• W3187715715 hasAuthorship W3187715715A5059193002 @default.
• W3187715715 hasAuthorship W3187715715A5077229668 @default.
• W3187715715 hasAuthorship W3187715715A5077805782 @default.
• W3187715715 hasAuthorship W3187715715A5085553146 @default.
• W3187715715 hasBestOaLocation W31877157151 @default.
• W3187715715 hasConcept C104317684 @default.
• W3187715715 hasConcept C121608353 @default.
• W3187715715 hasConcept C126322002 @default.
• W3187715715 hasConcept C143998085 @default.
• W3187715715 hasConcept C17923572 @default.
• W3187715715 hasConcept C182979987 @default.
• W3187715715 hasConcept C185592680 @default.
• W3187715715 hasConcept C207103383 @default.
• W3187715715 hasConcept C2776694085 @default.
• W3187715715 hasConcept C2777802072 @default.
• W3187715715 hasConcept C2778239845 @default.
• W3187715715 hasConcept C2779962180 @default.
• W3187715715 hasConcept C2780194787 @default.
• W3187715715 hasConcept C2780427987 @default.
• W3187715715 hasConcept C2780435969 @default.
• W3187715715 hasConcept C2780739268 @default.
• W3187715715 hasConcept C2781451048 @default.
• W3187715715 hasConcept C44249647 @default.
• W3187715715 hasConcept C50382708 @default.
• W3187715715 hasConcept C55493867 @default.
• W3187715715 hasConcept C71924100 @default.
• W3187715715 hasConcept C82381507 @default.
• W3187715715 hasConceptScore W3187715715C104317684 @default.
• W3187715715 hasConceptScore W3187715715C121608353 @default.
• W3187715715 hasConceptScore W3187715715C126322002 @default.
• W3187715715 hasConceptScore W3187715715C143998085 @default.
• W3187715715 hasConceptScore W3187715715C17923572 @default.
• W3187715715 hasConceptScore W3187715715C182979987 @default.
• W3187715715 hasConceptScore W3187715715C185592680 @default.
• W3187715715 hasConceptScore W3187715715C207103383 @default.
• W3187715715 hasConceptScore W3187715715C2776694085 @default.
• W3187715715 hasConceptScore W3187715715C2777802072 @default.
• W3187715715 hasConceptScore W3187715715C2778239845 @default.
• W3187715715 hasConceptScore W3187715715C2779962180 @default.

• next